Photo by nci from unsplash
e16162Background: Platinum/etoposide doublet is considered standard 1st-line therapy for PD NEC, however evidence to guide treatment beyond 1st-line regimens is lacking. Second-line small cell lung... Click to show full abstract
e16162Background: Platinum/etoposide doublet is considered standard 1st-line therapy for PD NEC, however evidence to guide treatment beyond 1st-line regimens is lacking. Second-line small cell lung...
Keywords:
2nd line;
efficacy 2nd;
line;
chemotherapy patients;
patients poorly;
line chemotherapy
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!